Komori
Nippi (7932) · InitiativeWorsened

Commercialization of the iPS Cell-Related Business and Strengthening of the Sales Structure

First written in FY2016. 20 of 32 entries say "Restated". Latest entry: 2026-11-10.

32entries
11years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020-Q1 – FY2023-Q32016: 320162017: 320172018: 420182019: 320192020: 120202021: 320212022: 320222023: 420232024: 220242025: 220252026: 42026
Same theme, other companies
Expansion of in-house product and service offerings for life sciencesA theme 7 companies write about · 0 as a headwind · 8 as a tailwind

Nippi moved to the "Worse" side of this theme in 2026.

The whole theme swung hardest in 2026: 1 of 6 companies on the "Worse" side.

0 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「Sales and profitability of biotechnology products have declined due in part to a shift in demand toward lower-priced products for research use, while medical-use gelatin has also been affected by weak sales at a major customer.」

    Sales and profitability of biotechnology products declined as demand shifted toward lower-priced products for research use, while medical-use gelatin was also affected by weak sales at a major customer.
  2. 2026-05-15WorsenedResults

    「一方、バイオ関連製品は、一部製品の販売が想定を下回ったことに加え、人件費や設備関連費用の増加等もあり、減収減益となりました。」

    国内外の製薬会社・民間研究機関向け販売が順調とされてきた一方、通期では一部バイオ関連製品の販売が想定を下回り、食品その他事業は減収減益となった。
  3. FY2026-H1RestatedAnnual report

    「Biotechnology products performed well, primarily among pharmaceutical companies and private research institutions in Japan and overseas, resulting in higher revenue and profit. As a result, revenue was ¥5,599 million, down 0.3% year on year, operating profit was ¥377 million, up 22.6%, and segment profit was ¥376 million, up 23.1%.」

    Biotechnology products for pharmaceutical companies and private research institutions in Japan and overseas performed well, and the Food and Other business posted lower revenue but higher profit.
  4. FY2025AdvancedAnnual report

    「Biotechnology products performed well, primarily among pharmaceutical companies and private research institutions in Japan and overseas, resulting in higher revenue and profit. As a result, revenue in the Food and Other business was ¥10,577 million, up 12.7% year on year, operating profit was ¥595 million, up 35.4%, and segment profit was ¥591 million, up 39.2%.」

    Biotechnology products for pharmaceutical companies and private research institutions in Japan and overseas performed well, and the Food and Other business posted higher revenue and profit.
  5. FY2025-H1AdvancedAnnual report

    「Organic grains performed well, supported by stable demand, while imported Italian food products for the food-service industry also performed well as demand recovered despite the impact of import exchange rates. Biotechnology products performed solidly, primarily among pharmaceutical companies and private research institutions in Japan and overseas, resulting in higher revenue and profit. As a result, revenue was ¥5,617 million, up 22.4% year on year, operating profit was ¥308 million, up 63.4%, and segment profit was ¥306 million, up 67.6%.」

    Biotechnology products for pharmaceutical companies and private research institutions in Japan and overseas performed solidly, and the Food and Other segment posted a 22.4% increase in revenue and a 67.6% increase in segment profit.
  6. FY2024-Q3RestatedAnnual report

    「Sales of biotechnology products also performed well, primarily among pharmaceutical companies and private research institutions in Japan and overseas.」

    Biotechnology products have continued to sell well, primarily to pharmaceutical companies and private research institutions in Japan and overseas.
  7. FY2024-Q2RestatedAnnual report

    「Biotechnology products also performed well, primarily among pharmaceutical companies and private research institutions in Japan and overseas.」

    Biotechnology products have continued to perform well, primarily for pharmaceutical companies and private research institutions in Japan and overseas.
  8. FY2024-Q1RestatedAnnual report

    「Biotechnology products also performed well, primarily among pharmaceutical companies and private research institutions in Japan and overseas.」

    Biotechnology products have continued to perform well, primarily for pharmaceutical companies and private research institutions in Japan and overseas.
  9. FY2023AdvancedAnnual report

    「Similarly, for the E8 fragments of human laminin-111 and 332 and for iMatrix-111 and 332, we established production cell lines incorporating our spERt technology, established the manufacturing processes, commercialized the products for reagent use and began sales.」

    For the iMatrix series, manufacturing processes for iMatrix-111 and 332 were established in addition to the existing products, and sales began as reagent-use products.
  10. FY2023-Q3RestatedAnnual report

    「Biotechnology products also performed well, primarily among pharmaceutical companies and private research institutions in Japan and overseas.」

    Biotechnology products have continued to perform well, primarily for pharmaceutical companies and private research institutions in Japan and overseas.
  11. FY2023-Q1RestatedAnnual report

    「Biotechnology products performed solidly, primarily among pharmaceutical companies and private research institutions in Japan and overseas.」

    Biotechnology products, including iPS-related products, have continued to perform solidly, primarily for pharmaceutical companies and private research institutions in Japan and overseas.
  12. FY2022Slower medical-use sales; solid reagent-use salesAnnual report

    「In the biotechnology business, medical-use sales of the iMatrix series slowed, but reagent-use sales remained solid both in Japan and overseas.」

    In the biotechnology business, including iPS-related products, slower medical-use sales coexisted with solid reagent-use sales in Japan and overseas.
  13. FY2022-Q3RestatedAnnual report

    「iPS-related products performed solidly during the COVID-19 pandemic, primarily among pharmaceutical companies and private research institutions in Japan and overseas.」

    iPS-related products have continued to perform solidly, primarily for pharmaceutical companies and private research institutions in Japan and overseas.
  14. FY2022-Q1RestatedAnnual report

    「iPS-related products performed well as the market grew, while Italian food products showed signs of recovery despite the state of emergency declaration.」

    iPS-related products have continued to perform well against a backdrop of market growth, and the focus on commercialization and strengthening the sales structure remains in place.
  15. FY2021RestatedAnnual report

    「The biotechnology business performed well, centered on regenerative medicine-related products.」

    The company has continued to state that the biotechnology business, including iPS-related products, is performing well, centered on regenerative medicine-related products.
  16. FY2021-Q3RestatedAnnual report

    「iPS-related products performed well as the market grew, while organic grains were supported by stable demand.」

    The company has continued to state that iPS-related products are performing well against a backdrop of market growth.
  17. FY2020RestatedAnnual report

    「The biotechnology business performed well as regenerative medicine progressed.」

    The biotechnology business, including iPS-related products, was described as performing well as regenerative medicine progressed, and the policy of commercializing products and strengthening the sales structure remains in place.
  18. FY2020-Q1RestatedAnnual report

    「Although iPS-related products performed well, sales of organic grains, Italian food products, fertilizer and cross-linked polyvinyl chloride fell below the same quarter of the previous year.」

    iPS-related products continued to perform well.
  19. FY2019AdvancedAnnual report

    「In February 2018, we began selling iMatri-221, which is suitable for the purification and maintenance culture of cardiomyocytes. We currently offer 3 types: 511, 411 and 221. We plan to develop several additional types of laminin in the future.」

    The iMatrix series added iMatrix-221 for cardiomyocytes, expanding the product range to 3 products: 511, 411 and 221.
  20. FY2019-Q3RestatedAnnual report

    「Sales of Italian food products, fertilizer, iPS-related products and cross-linked polyvinyl chloride also remained solid, but profit margins declined due to the impact of foreign exchange rates and other factors.」

    Sales of iPS-related products continued to perform solidly.
  21. FY2019-Q2RestatedAnnual report

    「Organic grains performed well, driven by the acquisition of new customers, while Italian food products, fertilizer, iPS-related products and cross-linked polyvinyl chloride also performed solidly.」

    iPS-related products continued to perform solidly.
  22. FY2019-Q1RestatedAnnual report

    「Organic grains performed well, driven by the acquisition of new customers, while fertilizer, iPS-related products and cross-linked polyvinyl chloride also performed solidly.」

    iPS-related products continued to perform solidly.
  23. FY2018AdvancedAnnual report

    「In addition, as a new business, we will sell iPS-related products, an area attracting considerable attention in regenerative medicine, in Japan and overseas through the joint venture Matrixome, Inc., established with Osaka University, a national university corporation. These products include the existing iPS cell culture substrate iMatrix511 and newly developed research products.」

    Domestic and overseas sales of iMatrix511 and newly developed research products through Matrixome continue to be identified as a new business in the regenerative medicine field.
  24. FY2018-Q3RestatedAnnual report

    「Organic grains and iPS-related products remained solid, but sales of BSE test kits, Italian food products and imported building materials declined amid weak conditions in their respective markets.」

    iPS-related products have continued to perform solidly, and the focus on commercialization and strengthening the sales structure remains in place.
  25. FY2018-Q2RestatedAnnual report

    「Organic grains and iPS-related products remained solid, but sales of BSE test kits, Italian food products and imported building materials declined.」

    iPS-related products continued to perform solidly.
  26. FY2017AdvancedAnnual report

    「The development plan for the area around Senju-Ohashi Station, in which we participate, is being promoted jointly by the government, businesses and local residents, with the aim of creating a vibrant, attractive community while ensuring consistency with Adachi Ward's higher-level plan, the Adachi Ward City Planning Master Plan.」

    Sales of iPS-related products for the current period through Matrixome, Inc. amounted to ¥92 million. The policy of strengthening the sales structure for universities and research institutions in Japan and overseas, as well as stable production capacity and the product lineup, remains in place.
  27. FY2017-Q3RestatedAnnual report

    「The iPS cell-related business and BSE test kits performed steadily, but sales of Italian food products, imported building materials and organic grains declined as the stronger yen lowered import prices.」

    The description that the iPS cell-related business is performing steadily has continued.
  28. FY2017-Q2RestatedAnnual report

    「The iPS cell-related business and BSE test kits performed steadily, but sales of Italian food products and imported building materials declined as the stronger yen lowered import prices.」

    The iPS cell-related business was described as performing steadily, and the focus on commercialization and strengthening the sales platform remains in place.
  29. FY2017-Q1RestatedAnnual report

    「The iPS cell-related business and BSE test kits performed steadily, but shipments of organic grains declined as volumes returned to normal in the absence of the temporary increase in sales in the same quarter of the previous year caused by concentrated shipments following a strike at ports in North America.」

    The iPS cell-related business continues to perform steadily, and the focus on commercialization and strengthening the sales platform remains in place.
  30. FY2016First statedAnnual report

    「The Company will strengthen its sales platform for universities and research institutions in Japan and overseas through the sales company established jointly with Osaka University, a national university corporation, while seeking to improve and stabilize production capacity.」

    The Company has announced plans to establish マトリクソーム, a joint venture with Osaka University, and to begin selling iMatrix-511 after April 2016.
Moved together

"Differentiating Cosmetics and Health Foods on the Back of Research Results" moved the same way as this thread, in the same document, in 6 of its 32 moves.

665554★123456
  1. ★This thread
  2. 1Differentiating Cosmetics and Health Foods on the Back of Research Results6×
  3. 2Overseas Market Entry and Strengthening the Operating Environment for the Leather-Related Business6×
  4. 3Retaining Domestic Customers and Capturing Overseas Demand in the Gelatin-Related Business5×
  5. 4Liquidity Risk Associated with Repayment of Borrowings and Bonds5×
  6. 5Development of High-Performance Products Based on Biomatrix Research5×
  7. 6Market Price Fluctuation Risk for Investment Securities4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Nippi's next results are scheduled for 2026-11-10. Read the earnings preview It last moved in the Results of 2026-11-10: "Worsened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Commercialization of the iPS Cell-Related Business and Strengthening of the Sales Structure | Nippi,Incorporated (7932) | Komori